

diabetes

A JOURNAL OF
THE AMERICAN
DIABETES
ASSOCIATION®

PERSPECTIVES IN DIABETES

Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy F.R. DERUBERTIS AND P.A. CRAVEN 1

ORIGINAL ARTICLES

Effects of chronic vanadate administration in the STZ-induced diabetic rat: the antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding U.H. MALABU, S. DRYDEN, H.D. MCCARTHY, A. KILPATRICK, AND G. WILLIAMS 9

Induction of tolerance to islet xenografts in a concordant rat-to-mouse model J.A. GOSS, Y. NAKAFUSA, E.H. FINKE, M.W. FLYE, AND P.E. LACY 16

ADP ribosylation by cholera toxin identifies three G-proteins that are activated by the galanin receptor: studies with RINm5F cell membranes S.L. GILLISON AND G.W.G. SHARP 24

Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes C. GELBER, L. PABORSKY, S. SINGER, D. McATEER, R. TISCH, C. JOLICOEUR, R. BUELOW, H. McDEVITT, AND C.G. FATHMAN 33

Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree W.H. HERMAN, S.S. FAJANS, F.J. ORTIZ, M.J. SMITH, J. STURIS, G.I. BELL, K.S. POLONSKY, AND J.B. HALTER 40

Peculiar T-cell signaling does not preclude positive selection in the diabetes-prone BB rat D. BELLGRAU, J.M. REDD, AND K.S. SELLINS 47

Biological actions of insulin are differentially regulated by glucose and insulin in primary cultured adipocytes: chronic ability to increase glycogen synthase activity F.B. LIMA, S. BAO, AND W.T. GARVEY 53

Maternal effect and familial aggregation in NIDDM: the CODIAB Study F. THOMAS, B. BALKAU, F. VAUZELLE-KERVROEDAN, L. PAPOZ, AND THE CODIAB-INSERM-ZENEGA GROUP 63

Growth hormone induces resistance to the mitogenic action of insulin through local IGF-I: studies in normal and pygmy T-cell lines M.E. GEFFNER, N. BERSCH, R.C. BAILEY, AND D.W. GOLDE 68

Effects of calcium antagonists on insulin-mediated glucose metabolism in skeletal muscle E.A. FOOT AND B. LEIGHTON 73

Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease E. KAWASAKI, H. TAKINO, M. YANO, S. UOTANI, K. MATSUMOTO, Y. TAKAO, Y. YAMAGUCHI, S. AKAZAWA, AND S. NAGATAKI 80

High genetic risk for IDDM in the Pacific Northwest: first report from the Washington State Diabetes Prediction Study R.E. ROWE, N.J. LEECH, G.T. NEPOM, AND D.K. McCULLOCH 87

Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen M. WAKISAKA, M.J. SPIRO, AND R.G. SPIRO 95

Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients J.B. MCGILL, D.J. SCHNEIDER, C.L. ARFKEN, C.L. LUCORE, AND B.E. SOBEL 104

Major histocompatibility complex-encoded antigen processing gene polymorphism in IDDM P.M. VAN ENDERT, R.S. LIBLAU, S.D. PATEL, L. FUGGER, T. LOPEZ, F. POCIOT, J. NERUP, AND H.O. MCDEVITT 110

Delayed onset of insulin activation of the insulin receptor kinase in vivo in human skeletal muscle G.R. FREIDENBERG, S. SUTER, R.R. HENRY, J. NOLAN, D. REICHART, AND J.M. OLEFSKY 118

Identification in islets of Langerhans of a new rat α_2 -adrenergic receptor S.Y. WANG AND D.T. PILKEY 127

Predictive value of lymphocyte antibodies for the appearance of diabetes in BB rats S. BERTRAND, C. VIGEANT, AND J.-F. YALE 137

A new transgenic mouse model of chronic hyperglycemia E.M. SCHAEFER, V. VIARD, J. MORIN, P. FERRÉ, L. PÉNICAUD, P. RAMOS, S.D. MAIKA, L. ELLIS, AND R.E. HAMMER 143

Associations of anti-GAD antibodies with islet cell antibodies and insulin autoantibodies in first-degree relatives of type I diabetic patients U. ROLL, M.R. CHRISTIE, E. STANDL, AND A.-G. ZIEGLER 154

RAPID PUBLICATION

GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes E. BJÖRK, L.A. VELLOSO, O. KÄMPE, AND F.A. KARLSSON 161



LETTER TO THE EDITOR

Maternal component in NIDDM transmission: how large an effect? 166



ORGANIZATION SECTION

INSTRUCTIONS FOR AUTHORS





**FOR TYPE II DIABETICS
LIFE IS DEMANDING
ENOUGH...**



TODAY'S LIFE DEMANDS INSULIN ON DEMAND

GLUCOTROL[®] (glipizide) provides patients with insulin when needed, responding on demand to meals and rising blood sugar.¹

GLUCOTROL, with insulin on demand, controls blood sugar quickly and effectively — all day and all night.¹

GLUCOTROL works in response to meals; returning insulin to near-normal levels once the meal challenge subsides.^{1,2}

When diet alone fails in NIDDM...*

Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets 


* Non-insulin-dependent diabetes mellitus.
As with all sulfonylureas, hypoglycemia may occur.



**Pratt
Pharmaceuticals**

Please see brief summary of prescribing information on last page.

INSULIN ON DEMAND RESPONDS TO MEALS— AND REMAINS AT BASAL LEVELS DURING FASTING



The effect of fasting on mean blood sugar and plasma insulin levels was measured in a 2-day study of six NIDDM patients whose blood sugar levels had been controlled by a single daily dose of 5 to 10 mg of GLUCOTROL. On the first day, patients were served three meals. On the second, they received no food. Patients received their usual dose of GLUCOTROL at the start of each day.¹

REFERENCES: 1. Clarke BF, Corrali RJM, Azzopardi J, Bhatta IP, Fraser DM, Duncan LJP. Clinical observations on glipizide: efficacy, duration of activity, and safety. In: *Glipizide: A Worldwide Review*. Princeton, NJ: Excerpta Medica; 1984:234-247. 2. Goebel R, Leb G. Effects of glyburide and glipizide on levels of immunoreactive insulin and blood sugar. In: *Glipizide: A Worldwide Review*. Princeton, NJ: Excerpta Medica; 1984:9-15.

Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful. **Information for Patients:** Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.


Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of DIFLUCAN (fluconazole) and GLUCOTROL has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received GLUCOTROL alone and following treatment with 100 mg of DIFLUCAN as a single daily oral dose for 7 days. The mean percentage increase in the GLUCOTROL AUC after fluconazole administration was 56.9% (range: 35 to 81).

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C: GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

FOR TYPE II DIABETES,

TODAY'S LIFE DEMANDS INSULIN ON DEMAND



When diet alone fails in NIDDM...

Glucotrol
(glipizide) 5-mg and 10-mg
Scored Tablets

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL, dialysis is unlikely to be of benefit.

DOSAGE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL; in general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL tablets are white, dye-free, scored, diamond-shaped, and imprinted as follows:

5 mg—Pfizer 411, 10 mg—Pfizer 412.
5 mg Bottles: 100's (NDC 0049-4110-66), (NDC 59012-411-66); 500's (NDC 0049-4110-73), (NDC 59012-411-73); Unit Dose 100's (NDC 0049-4110-41), (NDC 59012-411-41).

10 mg Bottles: 100's (NDC 0049-4120-66), (NDC 59012-412-66); 500's (NDC 0049-4120-73), (NDC 59012-412-73); Unit Dose 100's (NDC 0049-4120-41), (NDC 59012-412-41).

CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

Revised Jan. 1993



**Pratt
Pharmaceuticals**

diabetes

A JOURNAL OF THE AMERICAN DIABETES ASSOCIATION®

Editor

PHILIP E. CRYER, MD

Associate Editors

DAVID D. CHAPLIN, MD, PhD

GEORGE S. EISENBARTH, MD, PhD

MICHAEL L. McDANIEL, PhD

MIKE M. MUECKLER, PhD

M. ALAN PERMUTT, MD

JULIO V. SANTIAGO, MD

JOSEPH R. WILLIAMSON, MD

Editorial Assistant

MARY KHARIBIAN

Editorial Board

ALAIN D. BARON, MD

JOHN W. BAYNES, PhD

MICHAEL BROWNEE, MD

CHARLES F. BURANT, MD, PhD

NANCY J. COX, PhD

PIETRO DECAMILLI, MD

STEVEN C. ELBEIN, MD

JEAN GIRARD, PhD

MOREY W. HAYMOND, MD

GEORGE L. KING, MD

AMIRA KLIP, MD

KENNETH L. LUSKEY, MD

GERALD T. NEPOM, MD, PhD

LAWRENCE S. PHILLIPS, MD

GERALD I. SCHULMAN, MD, PhD,

FACP

ELIZABETH R. SEAQUIST, MD

MICHAEL P. STERN, MD

JOHN W. TURK, MD, PhD

MORRIS F. WHITE, PhD

LINDA S. WICKER, PhD

Publisher

SUSAN H. LAU

Editorial Director

PETER BANKS

Managing Editor

MATT PETERSEN

Assistant Managing Editor

SARAH L. ROBERTS

Production Editor

STACEY N. WAGES

Assistant Editors

KAREN L. INGLE

CHRISTIANN L. SHORTRIDGE

Director of Membership/

Subscription Services

GARY FRISCH

Customer Service Manager

STEPHEN LASEAU

Director of Advertising and Marketing

LEN BOSWELL

Advertising Manager

PEGGY B. ABBOTT

Advertising Assistant

PATTI THOMPSON

Advertising Representatives

Pharmaceutical Media, Inc.

440 Park Avenue South

New York, NY 10016

(212) 685-5010

Mission Statements for *Diabetes* and *Diabetes Care*

Diabetes publishes original research about the physiology and pathophysiology of diabetes mellitus. Submitted manuscripts can report any aspect of laboratory, animal, or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathologic pancreatic islet function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes. Studies in the areas of diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus are not published.

Diabetes Care is a journal for the health-care practitioner that is intended to increase knowledge, stimulate research, and promote better management of people with diabetes mellitus. To achieve these goals, the journal publishes original articles on human studies in the areas of epidemiology, clinical trials, behavioral medicine, nutrition, education, health-care delivery, medical economics, and clinical care. The journal also publishes clinically relevant review articles, clinical observations, letters to the editor, and public health/medical news or points of view. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other professionals.

All manuscripts and other editorial correspondence should be sent by first-class mail to Philip E. Cryer, MD, Editor, *Diabetes*, Division of Endocrinology, Diabetes, and Metabolism (Box 8127), Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110; (314) 362-7809.

Diabetes publishes only original material. When submitting a manuscript, authors must state in their transmittal letter that the material has not been published or submitted simultaneously to another journal. Accepted manuscripts incur a charge of \$25 per printed page.

Manuscripts should be prepared in accordance with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *New England Journal of Medicine* 324:424-428, 1991. "Instructions for Authors" containing specifications for manuscript preparation appears in the January and July issues.

All material published in *Diabetes* is copyrighted by the American Diabetes Association, Inc. All manuscripts submitted to *Diabetes* must include a transmittal letter stating the following before they will be considered for publication: "In consideration of ADA reviewing my (our) submission, the undersigned author(s) transfers, assigns, or otherwise conveys all copyright ownership to ADA in the event the work is published." Permission to reproduce copyrighted material from *Diabetes* will be granted for limited, noncommercial purposes. Requests for permission to use Figures or Tables or to adapt or reprint articles from this journal should be sent by letter or fax to Permissions Editor, American Diabetes Association, Inc., 1660 Duke Street, Alexandria, VA 22314; Fax: (703) 683-2890. Requests should be accompanied by a letter of permission from the senior author of the article.

Diabetes (ISSN 0012-1797) is published monthly by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, Virginia 22314. Professional membership dues include \$50 designated for *Diabetes*. Individual subscription rates are \$100 in the U.S., Canada, and Mexico (for Canada add 7% GST) and \$155 for all other countries. Single issues are \$12 in the U.S., Canada, and Mexico (for Canada add 7% GST) and \$31.50 for all other countries. Second-class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POST MASTER: Send change of address to *Diabetes*, American Diabetes Association, Journal Subscriptions, Dept. 0028, Washington, DC 20073-0028.

Diabetes is listed in *Science Citation Index*, *MEDLARS*, *Index Medicus*, and *Current Contents (Basic Science and Clinical Medicine)* data bases and *Automatic Subject Citation Alert*. *Diabetes* is available on-line on *BRS Colleague* (for more information, call 800-289-4277) and in machine-readable format from University Microfilms International. *Diabetes* is printed on acid-free paper starting with Vol. 37, 1988.

© 1994 by the American Diabetes Association, Inc.
Printed in the USA.

American Diabetes Association Officers 1993-1994

Chair of the Board

MICHAEL A. GREENE

President

JAMES R. GAVIN III, MD, PhD

Senior Vice President

PATRICIA D. STENGER, RN, CDE

Chair of the Board-Elect

DOUGLAS E. LUND

President-Elect

KATHLEEN L. WISNER, PhD, MD

Senior Vice President-Elect

LINDA M. SIMINIERO, RN, MS, CDE

Vice-Chair of the Board

DAVID H. MCCLURE

Vice President

FRANK VINICOR, MD

Vice President

DAVIDA F. KRUGER, MSN, C, RN, CDE

Secretary

SARA NOLEN

Treasurer

STEPHEN J. SATALINO

Office of the Executive

JOHN H. GRAHAM IV

RICHARD KAHN, PhD

CAROLINE STEVENS

 American
Diabetes
Association.

JANUARY AUTHOR INDEX

(Volume 43, Number 1)

- | | |
|------------------------|--------------------------|
| Akazawa, S., 80 | McDevitt, H., 33 |
| Arfken, C.L., 104 | McDevitt, H.O., 110 |
| | McGill, J.B., 104 |
| | Morin, J., 143 |
| Bailey, R.C., 68 | Nagataki, S., 80 |
| Balkau, B., 63 | Nakafusa, Y., 16 |
| Bao, S., 53 | Nepom, G.T., 87 |
| Bell, G.I., 40 | Nerup, J., 110 |
| Belgrau, D., 47 | Nolan, J., 118 |
| Bersch, N., 68 | |
| Bertrand, S., 137 | Olefsky, J.M., 118 |
| Björk, E., 161 | Ortiz, F.J., 40 |
| Buelow, R., 33 | |
| Christie, M.R., 154 | Paborsky, L., 33 |
| Codiab-Inserm-Zeneca | Papoz, L., 63 |
| Group, 63 | Patel, S.D., 110 |
| Craven, P.A., 1 | Pénicaud, L., 143 |
| | Pilkey, D.T., 127 |
| Derubertis, F.R., 1 | Pociot, F., 110 |
| Dryden, S., 9 | Polonsky, K.S., 40 |
| | |
| Ellis, L., 143 | Ramos, P., 143 |
| | Redd, J.M., 47 |
| Fajans, S.S., 40 | Reichart, D., 118 |
| Fathman, C.G., 33 | Roll, U., 154 |
| Ferré, P., 143 | Rowe, R.E., 87 |
| Finke, E.H., 16 | |
| Flye, M.W., 16 | Schaefer, E.M., 143 |
| Foot, E.A., 73 | Schneider, D.J., 104 |
| Freidenberg, G.R., 118 | Sellins, K.S., 47 |
| Fugger, L., 110 | Sharp, G.W.G., 24 |
| | Singer, S., 33 |
| Garvey, W.T., 53 | Smith, M.J., 40 |
| Geffner, M.E., 68 | Sobel, B.E., 104 |
| Gelber, C., 33 | Spiro, M.J., 95 |
| Gillison, S.L., 24 | Spiro, R.G., 95 |
| Golde, D.W., 68 | Standl, E., 154 |
| Goss, J.A., 16 | Sturis, J., 40 |
| | Suter, S., 118 |
| Halter, J.B., 40 | |
| Hammer, R.E., 143 | Takao, Y., 80 |
| Henry, R.R., 118 | Takino, H., 80 |
| Herman, W.H., 40 | Thomas, F., 63 |
| | Tisch, R., 33 |
| Jolicœur, C., 33 | |
| | Uotani, S., 80 |
| Kämpe, O., 161 | |
| Karlsson, F.A., 161 | van Endert, P.M., 110 |
| Kawasaki, E., 80 | Vauzelle-Kervroedan, F., |
| Kilpatrick, A., 9 | 63 |
| | Velloso, L.A., 161 |
| Lacy, P.E., 16 | Viard, V., 143 |
| Leech, N.J., 87 | Vigeant, C., 137 |
| Leighton, B., 73 | |
| Liblau, R.S., 110 | Wakisaka, M., 95 |
| Lima, F.B., 53 | Wang, S.Y., 127 |
| Lopez, T., 110 | Williams, G., 9 |
| Lucore, C.L., 104 | |
| | Yale, J.-F., 137 |
| Maika, S.D., 143 | Yamaguchi, Y., 80 |
| Malabu, U.H., 9 | Yano, M., 80 |
| Matsumoto, K., 80 | |
| McAteer, D., 33 | Ziegler, A.-G., 154 |
| McCarthy, H.D., 9 | |
| McCulloch, D.K., 87 | |

American Diabetes Association's 28th Research Symposium

Pancreas and Islet Cell Transplantation

DATE

March 18-20, 1994

LOCATION

San Diego Mission Valley Marriott
San Diego, California

PROGRAM TOPICS

Hormone Secretion and Metabolism
Strategies to Promote Long-Term Pancreas Graft
Function
Immunological Tolerance and Xenographs
Indications and Criteria for Transplantation in
Humans

ACCREDITATION/CONTINUING EDUCATION

The American Diabetes Association is accredited by the Accreditation Council for Continuing Education (ACCME) to sponsor continuing medical education for physicians. The Association designates this continuing medical education activity for 17.0 credit hours in Category 1 in the Physician's Recognition Award of the American Medical Association.

REGISTRATION INFORMATION

For a preliminary program and registration form, contact the American Diabetes Association, Meeting Services Department, 1660 Duke Street, Alexandria, VA 22314; PHONE: 703/549-1500, ext. 330; FAX: 703/836-7439.

TRAVEL INFORMATION

For special travel rates contact the American Diabetes Association's Travel Service at 800/232-3472, ext. 328.




NEW FROM THE AMERICAN DIABETES ASSOCIATION

Medical Management of Pregnancy Complicated by Diabetes


The Latest in ADA's Clinical Education Series

IN-DEPTH SECTIONS INCLUDE:

- ▶ Prepregnancy Counseling
- ▶ Contraception
- ▶ Psychological Impact of Diabetes and Pregnancy
- ▶ Monitoring
- ▶ Morning Sickness
- ▶ Nutritional Management
- ▶ Use of Insulin
- ▶ Diagnostic Testing and Fetal Surveillance
- ▶ Gestational Diabetes
- ▶ Neonatal Care of Infants
- ▶ GDM Postpartum Follow-Up



Softcover, 136 pages, 1993
Members \$29.95
Nonmembers \$33.50



- ▶ Tabbed and Completely Indexed for Quick Reference
- ▶ Concise, Practical, and Easy to Use
- ▶ Ideal for the Busy Clinician

"Outstanding! It clearly presents an enormous amount of extremely important and current information."

—Steven G. Gabbe, M.D.
Professor and Chairman, Ohio State Department of Obstetrics and Gynecology

"Comprehensive, well written, and timely in its scientific content and its emphasis on the various roles played by each member of the diabetes care team...a wonderful resource."

—Cheryl Hunt, RN, MSED, CDE
President, American Association of Diabetes Educators

"Succinct, well-organized, and easy to read."

—E. Albert Reece, M.D., American College of Nutrition

Medical Management of Pregnancy Complicated by Diabetes—the first and only comprehensive guide of its kind written for the busy health-care professional. You'll find this practical guide an indispensable reference you'll turn to again and again.

This complete package of counseling and management methods will help ensure the health of your patients and their babies.

Medical Management of Pregnancy Complicated by Diabetes is vital for all members of the health-care team. It is filled with techniques for managing and controlling blood glucose levels from the time of conception—a key element to ensuring a successful pregnancy, free of complications. And this valuable guide zeros in on specific treatment protocols, so you don't have to take time wading through volumes of reference material.

Order Today!

Don't delay! This all-in-one reference is a must for your professional practice. Simply complete the coupon below and return it with your payment, including postage and handling.

YES! Please send me _____ copies of *Medical Management of Pregnancy Complicated by Diabetes*: ADA Members, \$29.95; Nonmembers, \$33.50

Publications Subtotal _____

VA Residents add 4.5% State Sales Tax _____

Add Shipping & Handling (see Chart) _____

Total _____

Name _____

Address _____

City _____ State _____ Zip _____

P11J14

Please make checks payable to: American Diabetes Association

For credit card orders: ☐ MC ☐ VISA (Check One)

Print name as it appears on card _____

Credit card number _____ Exp. Date _____

Signature _____

Mail to: American Diabetes Association, 1970 Chain Bridge Road, McLean, VA 22109-0592

Shipping & Handling Chart (calculate using publications subtotal)
\$25.01-\$50.00 \$5.50 over \$50.00 10% of order

Please allow 2-3 weeks for delivery. Add \$3.00 to shipping and handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice. Pay by check, money order, or credit card.



American Diabetes Association's

41st Annual Advanced Postgraduate Course

January 28 - 30, 1994

The Westin Hotel at Copley Square, Boston, Massachusetts

FRIDAY, JANUARY 28

General Session—Atherosclerosis and Diabetes Mellitus

- The Epidemiology of Diabetes and Other Risk Factors for Cardiovascular Disease
- The Topography of Obesity and the Risk for Coronary Heart Disease
- Diabetes and Basic Mechanisms of Atherosclerosis
- The Relationship Between Diabetes, Dyslipidemia, and Coronary Heart Disease
- Plaque Regression: Will it Work for Patients with Diabetes?
- Management of Diabetic Dyslipidemia

Concurrent Workshops

- Diabetic Nephropathy: Prevention/Treatment
- Diabetic Neuropathy
- Diabetic Foot Care
- Nutritional Issues in the Management of NIDDM
- Dietary Supplements (Antioxidants and Magnesium) in the Treatment of Atherosclerosis
- New Forms of Therapy for Diabetes: Insulin, Insulin-like Sensitizers, Aminoguanidine

SATURDAY, JANUARY 29

General Session—DCCT Follow-up

- Additional Insights from the Diabetes Control and Complications Trial (DCCT)
- Complications/Adverse Effects
- Application: IDDM
- Implications: NIDDM
- The Economics: Cost/Benefit of Intensive Therapy

Concurrent Workshops

- Management of Thyroid Nodules
- Prevention and Treatment of Osteoporosis
- Management of Pituitary Tumors
- Dietary Recommendations and Carbohydrate Counting
- Insulin Management: What Are the Options?
- Educational Strategies: What Works Best?

Postgraduate Course Satellite Conference

Strategies for Implementing Tight Control in Patients with Type I and Type II Diabetes

When: January 26-27, 1994

Where: The Westin Hotel at Copley Square, Boston, MA


Sponsors: The American Diabetes Association's Council on Behavioral Medicine and Psychology and The National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases

Program Overview: The DCCT results have made it clear that tight metabolic control prevents and/or reduces the occurrence of the complications of diabetes. There is now a need to focus on how to achieve tight control across diverse patient groups. This conference will focus on the identification of barriers to achieving tight control and practical strategies for overcoming these barriers. The program will include interactive discussions with conference speakers, as well as hands-on small group workshops.

For more information:

Contact ADA Meeting Services Department (see address/phone number at right).

Minuteman Statue
Concord, MA



A highlight of the 41st Annual Advanced Postgraduate Course is the latest information on follow-up from the DCCT. The most up-to-date findings in clinically based research on topics in diabetes will also be presented by leading experts in the field. In addition, sessions focussing on endocrinology issues other than diabetes will be featured throughout the program. Call now for registration information, and join your colleagues for this outstanding educational opportunity!



SUNDAY, JANUARY 30

Concurrent Sessions —

Specific Topics in Endocrinology

Thyroid Disease in Pregnancy
The Role of Biochemical Evaluation in the Treatment of Osteoporosis
Medullary Thyroid Cancer
Endocrinology of Prostatic Disease
Polycystic Ovary Syndrome

Complicated Diabetes: Dealing with Concurrent Health Issues

The Relationship of Thyroid Disease to Diabetes
Diabetes Throughout the Hormonal Lifecycle of the Woman
Adaptive Diabetes Education for the Visually Impaired Patient

Concurrent Workshops

Presentation of the American Diabetes Association's Revised Nutritional Recommendations
The Role of the Diabetes Educator in Health Care Reform





Boston is a mix of colonial charm and urban sophistication. With an array of diverse and interesting attractions, one is never at a loss for something to do. Boston's many museums, concert halls, theaters, and restaurants are always abuzz with activity and excitement. From the internation-

ally acclaimed Museum of Fine Arts and Museum of Science to the famous Boston Symphony Orchestra and Boston Pops, the cultural and entertainment options are bountiful.

Located in the prestigious Copley Square, the Westin Hotel makes the most of everything Boston has to offer. The hotel is connected to the Copley Place Galleria, a shopping gallery of 100 fine shops, anchored by Neiman-Marcus and Tiffany's, a nine-screen cinema, restaurants, and a 60-foot skylit atrium. The hotel is serviced by two stops on the convenient "T" subway system, and is just a short walk to Newbury Street, a trendy collection of specialty shops, services, and cafes. There are more than 350 cultural activities within a one-mile radius of the hotel. The Westin Hotel is the ideal location for the 41st Annual Advanced Postgraduate Course.

USS Constitution/
Bunker Hill Monument

Fanueil Hall Market/
Custom House Tower



For Registration Information Contact:



Meeting Services Department,
1660 Duke Street, Alexandria, VA 22314
Phone: 703/549-1500, x330
Fax: 703/836-7439


ACT NOW!

The world's leading diabetes experts just wrote the only therapy manual you'll ever need.

Imagine not having to wade through volume after volume of diabetes therapy textbooks that consume too much of your time. Or having the expertise of more than 50 diabetes professionals at your fingertips in one new publication.

Well, the world's leading diabetes experts just wrote the only therapy manual you'll ever need. And it's easy to use!

Therapy for Diabetes Mellitus and Related Disorders has just been published by the American Diabetes Association and is the authoritative guide to diabetes therapy. It's a "how to" reference manual filled with all the information you need to provide the best care for your patients. Yet each of the 49 chapters average just seven pages, so you'll be able to digest the latest in treatment



- Treating diabetic nerve, eye, and kidney disease
- Controlling blood lipid abnormalities in diabetic patients
- Managing diabetic ketoacidosis and hyperglycemic hyperosmolar coma
- Much, much more!

Therapy for Diabetes Mellitus is also filled with more than 170 charts and tables, making each chapter easier to read and understand. Also, the manual's pocket-sized format will allow you to carry it with you for

and therapy in minutes.

You'll learn about:

- The latest drugs for treating diabetes, including sulfonylureas, metformin, and alpha-glucosidase inhibitors
- Genetic counseling for type I diabetes

quick reference whenever necessary.


So order your copy of *Therapy for Diabetes Mellitus and Related Disorders* today. And put the most comprehensive and easy-to-use therapy manual in your pocket.

Yes!

Please send me _____ copies of *Therapy for Diabetes Mellitus and Related Disorders* at \$22.45 for members or \$24.95 for nonmembers. I will be sure to add shipping and handling using the chart below.

Publication Total \$ _____
 Virginia Residents Add 4.5% sales tax \$ _____
 Orders outside the U.S., please add \$15 for each airmail shipment \$ _____
 Add shipping & handling (use chart) \$ _____
 GRAND TOTAL \$ _____

Shipping & Handling Chart			
Up to \$5.00	add \$1.75	\$25.01-\$50.00	add \$5.50
\$5.01-\$10.00	add \$3.00	over \$50.00	add 10% of order
\$10.01-\$25.00	add \$4.50		



Name _____

Address _____

City _____ State _____ Zip _____

Send your check or money order payable to:

American Diabetes Association®
 1970 Chain Bridge Road
 McLean, VA 22109-0592

P02J14

Allow 6-8 weeks for delivery. Add \$3.00 to shipping & handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice.